// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Pharmacologic Management of Takayasus Arteritis: A Systematic Review.

Kevin Lee - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Aspirin Dose in Kawasaki Disease - How Much is Enough?

Mercedes Chan - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Kawasaki disease

Aspirin

Subclinical Ultrasonographic Enthesitis in Patients with Psoriasis is Associated with Risk Markers for Psoriatic Arthritis

Ari Polachek - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

N/A

A Needs Assessment for New Models of Care for Pediatric Rheumatology in Ontario

Saunya Dover - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) that Reflects High, Moderate and Low Disease Activity as well as Minimal Disease Activity (MDA) in PsA

Suzanne Li - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 as a Measure of Quality of Life

Suzanne Li - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors

Vinod Chandran - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Increased Mortality Persons with Rheumatoid Arthritis is Partially Explained by Psychiatric Comorbidity: A Population Based Study

Sazzadul Khan - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Broad Exploration of the Pre-clinical Rheumatoid Arthritis (RA) Serum Proteome using Aptamer Based Technology

Xiaobo Meng - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The Effect of Administration Route for Osteoporosis Therapy on the Fracture-to-Fall Ratio

Richard Tse - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

Zoledronic acid

No Escalation of Therapy Despite High Disease Activity in the CATCH Cohort

Cheryl Barnabe - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Methotrexate

Guidelines for the Rational Use of Follow-up Cardiac Echocardiography to Screen for Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)

M. Hinchcliff - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

N/A

The Monetary Cost of Omega-3 Supplementation for Inflammatory Arthritis Patients: A Market Analysis

Jill Hall - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Updated Report of Real-World Use of Subcutaneous Abatacept in Canadian RA Patients: The Abatacept Best Care (ABC) Treat-To-Target (T2T) Study

Louis Bessette - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Abatacept

Factors Associated with Physical Therapy Use in Osteoarthritis of the Knee: Results from a Population-based Study

Eric Sayre - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Developing a Shared Care Model for the Treatment of Albertans with Inflammatory Arthritis (IA)

Dianne Mosher - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Impact of Baseline Disease Activity, Disease Duration and Enrolment Year on CDAI and Boolean Remission in Patients with Rheumatoid Arthritis Treated with Anti-TNF-Alpha Therapy: An Analysis from a Prospective, Observational Registry

Michael Starr - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Autoantibody Profiles in Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Cohort with and without Malignancy

Murray Urowitz - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Recurrent Benign Pneumatosis Intestinalis in a Patient with Systemic Sclerosis

Sahil Koppikar - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Non-Ischemic cardiomyopathy

Hydroxychloroquine

A Comparison of Pediatric vs Adult Subglottic Stenosis in ANCA-associated Vasculitis

Dax Rumsey - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

N/A

Copyright © 2026. QuantiNova All rights reserved